

## Zoono Group Limited (ASX: ZNO) ASX ANNOUNCEMENT

21 January 2022

## Update on legal claims

Zoono Group Limited (**Company**) (ASX: ZNO) advises that both of the legal claims pending against the Company have now been finalised.

The claim by Qingdao Zoono Biotech Ltd (QZB) has been dismissed by order of the Court for failure on the part of QZB to comply with Court orders relating to security costs and to otherwise take action to pursue its claim. Please refer to the Annual Report 2021 for further information.

The proceedings initiated by Sky Scrapers General Trading LLC (Sky Scrapers) following the Company's decision in 2020 to terminate its Distribution Agreement for the UAE and Oman has been resolved by mutual agreement of the parties.

In practical terms, in return for the payment of US\$700,000 to Sky Scrapers (split 50:50 between cash and shares), which payment will be partially offset by the return of all stock currently held by Sky Scrapers, the Company has re-acquired complete control of the distribution of its products in the Region.

While the Company does not accept that it had any liability to Sky Scrapers for termination of its Distribution Agreement, and had in fact initiated a sizeable counterclaim, the Company was persuaded to settle the claim to give certainty to its position in the Region and to avoid the significant management time and further legal costs which going to trial would undoubtedly involve.

The Company now has the option to wither run the region directly or appoint a new distributor and is already in negotiations with several parties.

Zoono Group Limited has made a provision of NZ\$1M in the Half-Year accounts for the settlement.

This announcement has been authorized and approved for release to ASX by the Board of Zoono Group Limited.

## For further information, please contact:

Zoono Group Limited Paul Hyslop Group Managing Director/CEO M: +64 21 659977 E: paul.hyslop@zoono.com.

Paul Ravlich Group CFO M: +64 21 0759176 E: <u>paul.ravlich@zoono.com</u>.

## About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributesa suite of scientifically validated, long-lasting and environmentally friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'Zoono molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com